By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - AbbVie on Wednesday reported better-than-expected quarterly ...

By holding these top income stocks in your portfolio, you can have a position in some great companies while also generating ...

AbbVie (ABBV) stock gains as the company raised its full-year earnings outlook despite a mixed performance in Q1 2026. Read ...

Our AbbVie (NYSE:ABBV | ABBV Price Prediction) call lands on the constructive side of the ledger after a noisy but ...

ABBV jumps 5% after a Q1 beat and higher 2026 guidance, but Skyrizi, Rinvoq and a deep pipeline may matter more for its post-earnings outlook ...

These stocks offer high yields, attractive valuations, significant upside, and can be terrific investments to buy right now.

Alvotech ( (ALVO)) just unveiled an update. Alvotech, a global biotech group specializing in biosimilar medicines and backed by a fully integrated development and manufacturing platform, has built a ...

Three years after AbbVie stood at the edge of a major patent cliff with the loss of exclusivity for immunology ...

US drugmaker AbbVie reported strong first-quarter 2026 results Wednesday, beating market expectations on both sales and ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...

Dividend stocks can be a pillar for long-term investing, generating passive income and offering stability even during tough ...

UCB will pay up to $2.2bn for Candid Therapeutics, betting on cizutamig and the wider T-cell engager rush in autoimmune disease.